Clinical and demographic factors in endometrial and ovary carcinoma: synchronous carcinoma vs stage IIIA endometrial carcinoma

Objective: To compare pre-surgical demographic and clinical factors and preoperative serum tumor marker values of patients with endometrial and ovarian synchronous carcinoma with those diagnosed with endometrial carcinoma with metastatic ovarian involvement (FIGO stage IIIA). Methods: A retrospective observational study including patients with endometrial and ovarian malignant tumors that were treated at Miguel Servet University Hospital, Zaragoza, Spain, since January 2000 to June 2020. All pathologic specimens were reviewed by two pathologists specialized in gynecological oncology. Results: Overall, 51 patients were included. 24 cases of them, were endometrial and ovarian synchronous primary carcinomas and the remaining 27 cases were endometrial tumors with adnexa. Parity, personal and family oncological history, arterial hypertension, diabetes, dyslipidemia, obesity and the prior use of hormone replacement therapy did not show significant differences between both groups. Age (p = 0.002), menopausal status (p = 0.029), abnormal uterine bleeding (p = 0.001), Ca 12.5 preoperative serum level (p = 0.038) and Ca 19.9 preoperative serum level (0.028) were factors with significant differences between both groups. In multivariate analysis, only abnormal uterine bleeding and Ca 19.9 values were independents factors. Conclusions: The presence of abnormal uterine bleeding and Ca 19.9 preoperative serum level could guide the clinician in the preoperative differential diagnosis between endometrial cancer with ovarian involvement and endometrial and ovarian synchronous carcinoma.

Endometrial and ovarian synchronous tumors; Endometrial cancer; Synchronous tumors; Ca 19.9 tumor marker

[1] Jain V, Sekhon R, Pasricha S, Giri S, Modi KB, Shrestha E, et al. Clinicopathological characteristics and prognostic factors of synchronous endometrial and ovarian cancers—a single-institute review of 43 cases. International Journal of Gynecological Cancer. 2017; 27: 938–946.

[2] Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE. Simultaneously detected endometrial and ovarian carcinomas—a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecologic Oncology. 2001; 83: 355–362.

[3] Oranratanaphan S, Manchana T, Sirisabya N. Clinicopathologic variables and survival comparison of patients with synchronous endometrial and ovarian cancers versus primary endometrial cancer with ovarian metastasis. Asian Pacific Journal of Cancer Prevention. 2008; 9: 403–407.

[4] Chen L, Zhao Q, Lv X. Characteristics and prognosis of coexisting adnexa malignancy with endometrial cancer: a single institution review of 51 cases. Archives of Gynecology and Obstetrics. 2011; 283: 1133–1137.

[5] Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Human Pathology. 1985; 16: 28–34.

[6] Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. Atlas of tumor pathology. Bethesda, MD: Armed Forces Institute of Pathology. 1998.

[7] Kandukuri SR, Rao J. FIGO 2013 staging system for ovarian cancer. Current Opinion in Obstetrics & Gynecology. 2015; 27: 48–52.

[8] Creasman W. Revised FIGO staging for carcinoma of the endometrium. International Journal of Gynaecology and Obstetrics. 2009; 105: 109.

[9] Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of Oncology. 2016; 27: 16–41.

[10] Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. International Journal of Gynecological Cancer. 2017; 27: 1534–1542.

[11] Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstetrics and Gynecology. 2005; 105: 575–580.

[12] Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecologic Oncology. 2004; 94: 456–462.

[13] Key TJ, Pike MC. The dose-effect relationship between ‘unop-posed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. British Journal of Cancer. 1988; 57: 205–212.

[14] Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371: 569–578.

[15] Bjørge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. International Journal of Cancer. 2007; 120: 378–383.

[16] Bodelon C, Wentzensen N, Schonfeld SJ, Visvanathan K, Hartge P, Park Y, et al. Hormonal risk factors and invasive epithelial ovarian cancer risk by parity. British Journal of Cancer. 2013; 109: 769–776.

[17] Usset JL, Raghavan R, Tyrer JP, McGuire V, Sieh W, Webb P, et al. Assessment of multifactor gene-environment interactions and ovarian cancer risk: candidate genes, obesity, and hormone-related risk factors. Cancer Epidemiology, Biomarkers & Prevention. 2016; 25: 780–790.

[18] Moro F, Leombroni M, Pasciuto T, Trivellizzi IN, Mascilini F, Ciccarone F, et al. Synchronous primary cancers of endometrium and ovary vs endometrial cancer with ovarian metastasis: an observational study. Ultrasound in Obstetrics & Gynecology. 2019; 53: 827–835.

[19] Uglietti A, Mazzei C, Deminico N, Somigliana E, Vercellini P, Fedele L. Endometrial polyps detected at ultrasound and rate of malignancy. Archives of Gynecology and Obstetrics. 2013; 289: 839–843.

[20] Bracco Suarez MB, Benetti-Pinto CL, Gibran L, Yela DA. Asymp-tomatic postmenopausal women: what are the risk factors for endometrial malignancies? A multicentric retrospective study. Gynecological Endocrinology. 2020; 1–4.

[21] van Niekerk CC, Bulten J, Vooijs GP, Verbeek ALM. The association between primary endometrioid carcinoma of the ovary and synchronous malignancy of the endometrium. Obstetrics and Gynecology International. 2010; 2010: 1–5.